 2. All patients must have measurable or evaluable disease. In general, liver and lung lesions should be at least 1 cm, and patients with node-only disease should have lesions of 1.5 cm in greatest dimension. Patients with disease confined to bone may be eligible if a measurable lytic defect is present or a serum marker is elevated 4 x ULN. The Principal Investigator is the final arbiter in questions related to measurability. Patients with a three-dimensional mass or pelvic sidewall fixation on bladder examination under anesthesia are considered to have measurable disease. 